Africa's next pharmaceutical manufacturing hub.
A 15-year demand forecast & investment thesis — driven by the rollout of Universal Health Insurance, backed by the Pharmaceutical Investment Acceleration Taskforce.
Why Tanzania.
Why now.
Four transformative forces are converging simultaneously. A young population, a policy mandate, a structural supply gap, and an institutional fast-track — at a single inflection point.
The Universal Health Insurance catalyst
UHI Act 2023 mandates universal coverage. Insurance trajectory from 8% baseline to 62% by Year 5, approaching 85% by Year 15 — a structural demand multiplier of 2.2× for insured populations.
A young, urbanising consumer base
26% under 15. Population growth 3.2% — among the highest in sub-Saharan Africa. Urbanisation at 5% per annum.
Structural undersupply
Over 80% of medicines, 90% of devices, and 99% of diagnostics imported. Zero API or vaccine manufacturing across the entire EAC.
Dual regional gateway
Member of both EAC and SADC blocs. Tariff-preferential access to 780M+ consumers. AMA treaty ratified.
First in Africa at WHO ML-3
TMDA — ISO 9001:2015. WHO-prequalified laboratory. ISO 17025 accredited. Continental Centre of Regulatory Excellence.
From 131 million to 608 million packs.
A front-loaded S-curve. Peak annual growth of 20–22% in years 1–5 as UHI rolls out, with steady population-driven expansion thereafter. Bottom-up across 120 essential SKUs.
Tanzania is ready to become Africa's pharmaceutical manufacturing hub. The direction is clear. The commitment is firm. The time is now.
Seven tiers of opportunity.
Each tier maps directly to a quantified gap in the TMDA registration data and MSD procurement patterns. Backed by 15% local preference, framework agreements, and Green-Lane facilitation.
Tier 01 · Essential Medicines
Pharmaceutical Manufacturing
WHO-GMP compliant production of human medicines. Substitute 20–40% of the $0.8–1.0B annual import bill.
Tier 02 · API & Excipients
API & Excipient Production
Zero API capacity in the entire EAC region. 100% of APIs imported. Highest policy priority.
Tier 03 · Vaccines & Biologics
Vaccines & Biologics
No human vaccines manufacturing in Tanzania. National health security priority — pandemic preparedness mandate.
Tier 04 · Small-Volume Parenterals
Small-Volume Parenterals
Zero ampoule or vial manufacturing nationally. Demand across hospitals, immunisation, and emergency medicine.
Tier 05 · Medical Devices
Medical Devices & Consumables
Over 90% imported. Active MSD JV opportunities in gloves and medical cotton via MSD Medipharm.
Tier 06 · Diagnostics & IVDs
Diagnostics & IVDs
Approximately 99% imports. Malaria, HIV, TB, pregnancy testing — all currently sourced offshore.
A coordinated institutional architecture.
Four pillars. One table. PIAT brings senior decision-makers from each institution together — concurrent, not sequential, approvals.
PIAT
Pharmaceutical Investment Acceleration Taskforce. Whole-of-government fast-track. Direct ministerial escalation path.
TMDA
First African regulator at WHO ML-3. ISO 9001:2015. WHO-prequalified laboratory. 60-day registration for local products.
MSD
$491M annual procurement. 8,800+ facilities served. Framework Agreements provide multi-year revenue visibility.
TISEZA
Investment authority under President's Office. Act of Parliament No. 6 of 2025. SEZ/EPZ licensing under one roof.
Concurrent processing.
Not sequential approvals.
Licensing, permits, land access, taxation, product registration, and infrastructure — all moving in parallel. Predictable, time-bound decisions for serious pharmaceutical investors.
Mloganzila & Kibaha.
Purpose-built. Cluster-ready.
Integrated ecosystems bringing manufacturers, regulators, research capacity, and logistics infrastructure onto a single coordinated platform.
01 Mloganzila Cluster
Pharmaceutical Manufacturing Hub Cluster 1 — purpose-built integrated ecosystem with embedded TMDA presence and shared compliance infrastructure.
02 Kibaha Cluster
Cluster 2 — 56 km from Dar city centre, 8 km from Kwala SGR Depot. MSD Medipharm offering up to 40,000 sqm to qualified JV partners.
Shared Pharmaceutical Laboratory Facility
Government-backed investment serving both clusters. Bioequivalence studies, advanced quality testing, WHO-PQ and GMP regulatory support — shared infrastructure that lowers entry barriers and shortens time-to-market.
From Expression of Interest to launch.
A predictable, time-bound process. PIAT brings every approving authority into a single coordinated review — five steps from EOI to scale-up.
Expression of Interest
Submit through PIAT secretariat. Capabilities, intent, indicative capital, product focus.
Technical Review
Multi-agency assessment of strategic fit. Site visits and management meetings.
Joint Structuring
Localisation roadmap. Tech transfer commitments. Incentives package & land allocation.
Green-Lane Fast-Track
Concurrent processing. Licences, permits, registrations, land, utilities — moving in parallel.
Establishment & Launch
Construction, GMP certification, product registration, market launch under PIAT monitoring.
News &
press releases.
A look inside.
Invest in Tanzania's
pharmaceutical future.
Medicines made in Tanzania. Trusted in Africa. Accepted globally. The Government is ready — decisively, in good faith, and in partnership.